<div id="readability-page-1"><p>Wells Fargo analyst Larry Biegelsen maintained a Buy rating on NeuroPace today and set a price target of $16.00.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>Biegelsen covers the Healthcare sector, focusing on stocks such as Cooper Co, Johnson &amp; Johnson, and Glaukos. According to TipRanks, Biegelsen has an average return of <span>4.2%</span> and a 54.20% success rate on recommended stocks. </p> <p>In a report released on December 10, J.P. Morgan also maintained a Buy rating on the stock with a $20.00 price target.</p></div>

NPCE

<p>Wells Fargo analyst Larry Biegelsen maintains a Buy rating for NeuroPace with a $16.00 price target. J.P. Morgan also keeps a Buy rating with a $20.00 target. Biegelsen, focusing on healthcare stocks, has a 4.2% average return and a 54.20% success rate. TipRanks offers a Cyber Monday sale on its Premium service for investment insights.</p>

Wells Fargo Sticks to Their Buy Rating for NeuroPace (NPCE)